Document is current

Article History

Accepted: 10 June 2025

First Online: 12 July 2025

Declarations

:

: Prithviraj Bose: Grants (Incyte, CTI, MorphoSys, Kartos, Telios, Ionis, Disc, Blueprint, Cogent, Geron, Janssen, Sumitomo, BMS, Karyopharm); consulting fees (Incyte, BMS, CTI, GSK, AbbVie, MorphoSys, Karyopharm, PharmaEssentia, Blueprint, Cogent, Novartis, Jubilant, Morphic, Ono, Sumitomo); honoraria for lectures/advisory boards (Incyte, Blueprint, GSK, CTI, AbbVie, Sumitomo, PharmaEssentia). Zhijian Xiao: no competing interests to declare. Hans C. Hasselbalch: Data Monitoring Board honoraria from AOP Health and grants from Novartis. Josef T. Prchal: AbbVie: Research Funding; PharmaEssentia: Research Funding. Minghui Duan: no competing interests to declare. Abdulraheem Yacoub: Consulting fees (Incyte, CTI Pharma, PharmaEssentia, Pfizer, Novartis, Acceleron Pharma, Servier, AbbVie, Apellis, Gilead, Notable Labs); meeting/travel support (Incyte). Raajit K. Rampal: Grants (Incyte, Ryvu, MorphoSys, Zentalis); consulting fees (MorphoSys, CTI, GSK, Stemline, Blueprint, SDP, Servier, Zentalis, BMS, Galectco, AbbVie, PharmaEssentia, Cogent, Kartos); honoraria for lectures/advisory boards (Protagonist, Karyopharm, GSK); monitoring or advisory board (Kartos). Jean-Jacques Kiladjian; grants and personal fees from AOP Health, and personal fees from Novartis, BMS/Celgene, AbbVie, and PharmaEssentia. Gabriela Hobbs: Grants (Incyte); consulting fees (PharmaEssentia, Protagonist, AbbVie, GSK, Pfizer, Novartis, MorphoSys, Cogent, Pharmaxis); monitoring or advisory board (PharmaEssentia, Protagonist, AbbVie, GSK, Pfizer, Novartis, MorphoSys); stock/stock options (Regeneron Pharmaceuticals). Tsewang Tashi: Blueprint (consultancy, research funding), PharmaEssentia (consultancy, research funding), Cogent (consultancy, research funding), CITI Biopharma (consultancy), Italfarmaco (research funding), and Telios (research funding) Kazuya Shimoda: a consultant for Sierra Oncology, Inc. and reports research funding from AbbVie G.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. and honoraria from Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K., and is a member of an advisory committee for AbbVie G.K. Keita Kirito: received honoraria for lectures, presentations, speaking engagements, manuscript writing, and educational events from AbbVie G.K., Novartis Pharma K.K., PharmaEssentia Japan K.K., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. Harinder Gill: Consulting fees/Speaker fees from Abbvie, Bristol Myers Squibb, GSK, MSD, Novartis, PharmaEssentia Corporation and Pfizer, Advisory board for Abbvie, Bristol Myers Squibb, GSK, Novartis, PharmaEssentia Corporation and Pfizer, Research support from Celgene, MSD, Novartis and PharmaEssentia Corporation, Conference support from Bristol Myers Squibb, MSD, Novartis, Otsuka, PharmaEssentia and Pfizer. Hsin-An Hou: Consulting fees/Speaker fees/ honoraria from Abbvie, Bristol Myers Squibb, GSK, MSD, Novartis, PharmaEssentia Corporation and Pfizer, Research support from Novartis and PharmaEssentia Corporation, Conference support from Bristol Myers Squibb, MSD, Novartis, Otsuka, PharmaEssentia and Pfizer. Sung-Eun Lee: no competing interests to declare. Jian Huang: no competing interests to declare. Bing Li: no competing interests to declare. Albert Qin: serving as the chief medical officer of PharmaEssentia Corporation. Lennex Hsueh-Lin Yu: employed at PharmaEssentia. John Mascarenhas: Grants (PharmaEssentia, Novartis, Roche, Geron, Abbie, Kartos, Karyopharm); consulting fees (PharmaEssentia, CTI, Incyte, Roche, Novartis, Merck, Geron, AbbVie, BMS, Kartos, MorphoSys, Galecto, Imago); honoraria for lectures/advisory boards (BMS); monitoring or advisory board (Incyte, Galecto); meeting/travel support (Kartos). Ruben A. Mesa: Consulting fees (Incyte, PharmaEssentia, CTI, AbbVie, GSK, BMS, Genentech).